셀트리온 제약

◯ Breast cancer

■ Metastatic breast cancer

It is administered as follows for the treatment of patients with HER2 (Human Epidermal growth factor Receptor 2 protein) positive metastatic breast cancer.

1. Monotherapy for patients who have received one or more chemotherapy treatments for metastatic disease

2. In combination with paclitaxel or docetaxel for patients who have not received chemotherapy for metastatic disease

3. Co-administration with aromatase inhibitors in postmenopausal patients who are hormone receptor-positive and have not previously received trastuzumab

■ Early breast cancer

It is administered as follows for the treatment of patients with HER2-positive early breast cancer.

1. After receiving chemotherapy (radiotherapy if necessary) before or after surgery

2. Co-administration with paclitaxel or docetaxel after adjuvant chemotherapy with doxorubicin and cyclophosphamide

3. Combined administration with adjuvant chemotherapy of docetaxel and carboplatin

4. For locally advanced (including inflammatory) disease or tumors with a diameter of > 2 cm, this drug is administered as neoadjuvant therapy before surgery, followed by combined administration of this drug and chemotherapy, and then as adjuvant therapy after surgery.

◯ Metastatic gastric cancer

Platinum-based drugs plus capecitabine or 5-FU in combination with HER2-positive metastatic gastric adenocarcinoma or gastroesophageal junction adenocarcinoma who have not previously received chemotherapy for metastatic disease

150mg/Vial : Trastuzumab 150mg

440mg/Vial : Trastuzumab 440mg